title: Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs.
abstract: Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induced unprecedented 100% protection of guinea pigs from high-dose aerosol challenge with Mycobacterium tuberculosis, suggesting a strategy for enhancing and prolonging the efficacy of BCG.
authors.affiliation: Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom.
authors.forename: A
authors.initials: A
authors.lastname: Williams
authors.forename: N P
authors.initials: NP
authors.lastname: Goonetilleke
authors.forename: H
authors.initials: H
authors.lastname: McShane
authors.forename: Simon O
authors.initials: SO
authors.lastname: Clark
authors.forename: Graham
authors.initials: G
authors.lastname: Hatch
authors.forename: S C
authors.initials: SC
authors.lastname: Gilbert
authors.forename: A V S
authors.initials: AV
authors.lastname: Hill
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000235:genetics* / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology*; D006168:Guinea Pigs; D011212:Poxviridae / Q000235:genetics*; D014376:Tuberculosis / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000942:Antigens, Bacterial; D001500:BCG Vaccine; D014614:Vaccines, Synthetic; C065036:antigen 85, Mycobacterium bovis